You have 9 free searches left this month | to do more

nivolumab

Nivolumab is a drug used to treat Melanoma, Metastatic Melanoma, Renal Cell Carcinoma, and other conditions. Nivolumab is being actively studied in 635 studies and prior, has been studied in 83.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionIvan S Moiseev
National Cancer Institute (NCI)Memorial Sloan Kettering Cancer CenterInna Chen, MD
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsDana Farber Cancer InstituteTheodore Sunki Hong
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab
Recruiting
  • Melanoma Stage III
  • Melanoma
  • Philadelphia, Pennsylvania
    Abramson Cancer Center, University of Pennsylvania
2021-05-14
May 14, 2021
D
Study of TLR9 Agonist CMP-001 in Combination With Nivolumab vs. Nivolumab
Recruiting
  • Melanoma
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-11-16
Nov 16, 2021
A
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer
Not yet recruiting
  • Gastric Cancer
  • Gastroesophageal Junction Adenocarcinoma
  • Whittier, California
    Innovative Clinical Research Institute
2021-12-02
Dec 2, 2021
I
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)
Not yet recruiting
  • Muscle-Invasive Bladder Carcinoma
  • Nivolumab + Nab-paclitaxel
  • Nivolumab
  • Milan, MI, Italy
    Genitourinary Medical Oncology - IRCCS San Raffaele Hospital and
2021-05-03
May 3, 2021
K
Regorafenib and Nivolumab Simultaneous Combination Therapy - 2020
Completed
  • Advanced and Metastatic Solid Tumor
  • Kashiwa, Chiba, Japan
    NationalCCHE
2021-04-23
Apr 23, 2021
C
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
Active, not recruiting
  • Glioblastoma
  • Nivolumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
2021-05-21
May 21, 2021
D
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
2021-11-18
Nov 18, 2021
D
Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN
Active, not recruiting
  • Squamous Cell Carcinoma of the Head and Neck
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
2021-07-22
Jul 22, 2021
N
Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung Cancer
Active, not recruiting
  • Non-Small Cell Lung Cancer
  • Singapore, Singapore
  • +2 more
2021-04-27
Apr 27, 2021
C
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
Not yet recruiting
  • Gastric Cancer
  • Chemotherapy Effect
  • Nivolumab plus SOX
  • +2 more
  • (no location specified)
2021-08-15
Aug 15, 2021
B
A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors
Active, not recruiting
  • Solid Tumors
  • Nivolumab
  • Guangzhou, Guangdong, China
  • +1 more
2021-09-17
Sep 17, 2021
T
Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery
Recruiting
  • Cutaneous Squamous Cell Carcinoma
  • Amsterdam, Noord Holland, Netherlands
    NKI-AVL
2020-11-05
Nov 5, 2020
N
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
Active, not recruiting
  • Ann Arbor Stage III Lymphoma
  • +4 more
  • Bethesda, Maryland
  • +2 more
2021-08-27
Aug 27, 2021
T
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
Recruiting
  • Breast Cancer
  • Amsterdam, Netherlands
    NKI-AVL
2021-09-28
Sep 28, 2021
V
Neoadjuvant Nivolumab for Oral Cancer Combined With FDG and Anti-PD-L1 PET/CT Imaging for Response Prediction
Active, not recruiting
  • Oral Cavity Squamous Cell Carcinoma
  • Nivolumab
  • Amsterdam, Noord-Holland, Netherlands
    VU University medical center
2021-10-06
Oct 6, 2021
D
Nivolumab Plus Ipilimumab in Thyroid Cancer
Active, not recruiting
  • Thyroid Cancer
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-07-15
Jul 15, 2021
B
A Phase 1, Bioavailability Study of Relatlimab in Combination With Nivolumab
Active, not recruiting
  • Cancer
  • Hackensack, New Jersey
    Hackensack University Medical Center
2021-09-13
Sep 13, 2021
S
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Recruiting
  • Microsatellite Stable (MSS) Colorectal Adenocarcinomas
  • Colorectal Adenocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2021-08-18
Aug 18, 2021
M
Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)
Active, not recruiting
  • Bladder Cancer
  • Melanoma
  • Nivolumab
  • Nivolumab plus Ipilimumab
  • Farmington, Connecticut
  • +4 more
2021-10-01
Oct 1, 2021
R
Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma
Active, not recruiting
  • Renal Cell Carcinoma
  • Washington, District of Columbia
  • +1 more
2021-07-26
Jul 26, 2021
S
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
2021-08-18
Aug 18, 2021
Y
A Phase 2, Open-label Trial of Consolidation Nivolumab After Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma
Not yet recruiting
  • Locally Advanced Nasopharyngeal Carcinoma
  • Nivolumab
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
2021-05-26
May 26, 2021
T
Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy
Withdrawn
  • Nasopharyngeal Carcinoma
  • Nivolumab
  • (no location specified)
2021-04-28
Apr 28, 2021
D
NeoVax With Nivolumab in Patients With Ovarian Cancer
Recruiting
  • Ovarian Cancer
  • Nivolumab
  • +2 more
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-06-21
Jun 21, 2021
A
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
Recruiting
  • Metastatic Melanoma
  • Hypofractionated Radiation Therapy (HFRT)
  • +2 more
  • Philadelphia, Pennsylvania
    Abramson Cancer Center
2021-03-30
Mar 30, 2021